External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

被引：0
|
作者：
Paganelli, G. [1 ]
Rossetti, C. [2 ]
Aglietta, M. [3 ]
Messina, C. [4 ]
Versari, A. [5 ]
Michalski, J. M. [6 ]
O'Sullivan, J. M. [7 ]
Parker, C. [8 ,9 ]
Garcia-Vargas, J. E. [10 ]
Sartor, A. [11 ]
Finkelstein, S. E. [12 ]
机构：
[1] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, IT, Italy
[2] AO Osped Niguarda Ca Granda, Milan, Italy
[3] IRCCS Candiolo, Candiolo, TO, Italy
[4] AO Papa Giovanni XXIII, Bergamo, IT, Italy
[5] IRCCS AO Arcispedale S Maria Nuova, Reggio Emilia, IT, Italy
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Queens Univ, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[9] Inst Canc Res, Sutton, Surrey, England
[10] Bayer HealthCare, Whippany, NJ USA
[11] Tulane Canc Ctr, New Orleans, LA USA
[12] 21st Century Oncol, Scottsdale, AZ USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F31
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [41] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Parker, C.
    Heinrich, D.
    Bottomley, D.
    Hoskin, P.
    Franzen, L.
    Solberg, A.
    Pawar, V.
    Reuning-Scherer, J.
    O'Bryan-Tear, C. G.
    Nilsson, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S689 - S689
  • [44] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Matt Shirley
    Paul L. McCormack
    Drugs, 2014, 74 : 579 - 586
  • [45] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Shirley, Matt
    McCormack, Paul L.
    DRUGS, 2014, 74 (05) : 579 - 586
  • [46] Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use
    Shirley M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2016, 32 (3) : 98 - 103
  • [47] Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.
    Omlin, Aurelius Gabriel
    Daugaard, Gedske
    Peer, Avivit
    Reichegger, Hermann
    Neumann, Avivit
    Rosenbaum, Eli
    Desax, Marie-Claire
    Neiman, Victoria
    Petersen, Peter Meidahl
    Mueller, Joachim
    Cathomas, Richard
    Gottfried, Maya
    Sarid, David
    Gez, Eli
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Mortensen, Jann
    Gillessen, Silke
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study
    Nilsson, Sten
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [49] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [50] Hematotoxicityand non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Ahmadzadehfar, H.
    Azgomi, K.
    Rogenhofer, S.
    Bundschuh, R.
    Kuerpig, S.
    Thomas, L.
    Essler, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S738 - S739
12345